Home > Insider Trading > Filing (0001127602-12-023459)

Filing Details

Accession Number:: 0001127602-12-023459
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2012-08-01 19:50:32
Reporting Period:: 2012-08-01

Filing Date:: 2012-08-01
Accepted Time:: 2012-08-01 19:50:32
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
318154	Amgen Inc	AMGN	Biological Products, (No Disgnostic Substances) (2836)	953540776

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1199306	Anna Richo	One Amgen Center Drive Thousand Oaks CA 91320-1799	Svp & Cco	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2012-08-01	5,125	$62.63	41,992	No	4	M	Direct
Common Stock	Disposition	2012-08-01	5,125	$0.00	36,867	No	5	G	Direct
Common Stock	Acquisiton	2012-08-01	5,125	$0.00	15,381	No	5	G	Indirect	The Nicholas A. Moore and Anna S. Richo Family Trust
Common Stock	Disposition	2012-08-01	5,125	$83.06	10,256	No	4	S	Indirect	The Nicholas A. Moore and Anna S. Richo Family Trust

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	5	G	Direct
No	5	G	Indirect	The Nicholas A. Moore and Anna S. Richo Family Trust
No	4	S	Indirect	The Nicholas A. Moore and Anna S. Richo Family Trust

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Nqso (Right to Buy)	Disposition	2012-08-01	5,125	$0.00	5,125	$62.63

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0	2009-07-31	2015-07-31	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	2,342	Indirect	401(k) Plan

Footnotes

These shares are being transferred to the reporting person's Family Trust.
These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,425 RSUs which fully vest on 4/28/2013; 2,900 RSUs which vest in two equal annual installments of 1,450 each commencing 4/26/2013; 20,000 RSUs which fully vest on 10/28/2013; 7,500 RSUs which vest in two equal installments of 2,475 each on 4/25/2013 and 4/25/2014 and one installment of 2,550 on 4/25/2015; and 3,350 RSUs which vest in three installments of 1,105, 1,106 and 1,139 on 4/27/2014, 4/27/2015 and 4/27/2016, respectively. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.
These shares include 1,675 shares of common stock acquired under the Company's Employee Stock Purchase Plan.
These shares include 17 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.
The price reported is an average price. The prices ranged from $83.04 to $83.11 per share. Full information regarding the number of shares sold at each separate price within the range set forth above is available upon request by the SEC staff, the issuer or a security holder of the issuer.
These are shares acquired under the Company's 401(k) Plan and represent interests in the Company's stock fund as of this filing.